Our Mission:
To develop drugs that target components of the ubiquitin system, based on our expanding proprietary knowledge.

Our Vision:
Proteologics aspires to become a fully integrated pharmaceutical company and a leader in the emerging field of the ubiquitin-related drugs.

Company Profile:
From Target Discovery to Drug Development
Proteologics identifies new correlations between ubiquitin pathway components and pathological conditions. Once specific E3 targets are discovered and validated, we proceed to establishing proprietary technologies for the accelerated hit-to-lead drug discovery process. Proteologics' recognized competencies are built through a number of internal programs and partnerships, including a strategic R&D collaboration with Teva Pharmaceutical Industries Ltd.

Company Background:
Proteologics Inc. was founded in 1999 and is a private corporation registered in Delaware, USA. Proteologics Inc. R&D is performed at its wholly owned Israeli subsidiary, Proteologics Ltd.